Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70) announced on September 23, 2026, that it proposes to issue 75,268 common shares at a deemed price of $0.18 per share to settle $13,548.39 in accrued share-based consulting compensation owed to a former consultant. The company simultaneously disclosed the resignation of director Daniel Vice, effective September 17, 2026. Both developments may be of interest to investors monitoring Doseology's corporate governance and capital structure.

Key Points

  • Doseology Sciences Inc. (CSE: MOOD | OTCQB: DOSEF | FSE: VU70) is a Kelowna, British Columbia-based consumer product innovation company.
  • The company proposes to issue 75,268 common shares at $0.18 each to settle $13,548.39 in accrued consulting compensation owed to a former consultant.
  • Settlement completion is anticipated on or about September 30, 2026, subject to corporate, securities law, and CSE requirements being met.
  • Investors should watch for confirmation that all regulatory and CSE conditions have been satisfied ahead of the anticipated settlement date.

Doseology's Proposed Shares-for-Debt Settlement Terms

Doseology Sciences proposes to issue an aggregate of 75,268 common shares at a deemed price of $0.18 per share, settling $13,548.39 in accrued share-based consulting compensation owed to a former consultant. The release states the deemed issue price was determined by reference to the closing price of the company's common shares on the CSE on the trading day immediately preceding the announcement, in accordance with applicable CSE policies. The settlement shares will be subject to applicable resale restrictions under Canadian securities laws and any hold period imposed under CSE policies.

Anticipated Timeline and Regulatory Conditions

The company anticipates completing the settlement on or about September 30, 2026, contingent on the satisfaction of applicable corporate, securities law, and CSE requirements. The announcement makes clear that completion is not guaranteed, noting risks including the possibility that required documentation may not be finalised, that CSE may impose additional conditions, or that the indebtedness amount or share count could differ from currently disclosed figures. Investors may be watching for formal confirmation once all conditions are met and the shares are formally issued.

Director Daniel Vice Resigns from Doseology Board

Doseology also disclosed that Daniel Vice resigned as a director of the company, effective September 17, 2026. The announcement offered no further detail regarding the circumstances of the resignation or whether the board intends to appoint a replacement director. The company stated it wishes Mr. Vice well in his future endeavours. Changes to board composition can be relevant to investors assessing a company's corporate governance structure, and the disclosure was made in accordance with standard continuous disclosure obligations.